PMGC Holdings Stock Price, News & Analysis

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), announced plans to file a Schedule 13D disclosing a 5.09% ownership stake in Alaunos Therapeutics (TCRT). The stake represents 83,500 shares of the clinical-stage oncology-focused cell therapy company, based on Alaunos' 1,639,521 outstanding shares as of May 5, 2025.

PMGC Capital believes Alaunos is undervalued and sees significant potential for shareholder value creation. Alaunos is currently exploring strategic alternatives, including mergers, acquisitions, asset sales, and strategic partnerships. PMGC Capital plans to engage with Alaunos' management to explore strategic opportunities, particularly in fintech and cryptocurrency sectors.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has signed a binding term sheet with Modulant Biosciences for exclusive global licensing rights of EL-22 in animal health applications. The agreement covers worldwide rights (excluding South Korea) for developing and commercializing EL-22 as a feed additive, focusing on a probiotic approach to muscle preservation in livestock.

The intellectual property includes U.S. Patent 8,470,551 and two patent applications. Under the financial terms, Modulant will pay Northstrive a share of revenues from sublicensing and commercial activities, with the royalty rate decreasing after reaching a certain threshold. The agreement also includes provisions for co-ownership of new intellectual property and annual updates on commercialization efforts.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has filed four new patent applications for its drug candidates EL-22 and EL-32. The patents cover two key areas: animal market applications and muscle loss treatment in obese patients, particularly in combination with GLP-1 receptor agonists.

The patent applications include:

• EL-22 for muscle growth in animals
• EL-32 as a standalone therapy for obesity-related muscle loss
• EL-32 in combination with GLP-1 drugs
• EL-32 as an animal feed additive

These additions bring Northstrive's intellectual property portfolio to 8 patent applications and 5 issued patents, with protection across major markets including the USA, Japan, China, and Korea. The company's engineered probiotic platform aims to preserve muscle mass while reducing fat mass in obesity treatment, with potential expansion into animal health markets.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced that Co-Founder Deniel Mero was featured in a Bear Bull Traders interview discussing recent FDA preliminary meeting responses. The responses support their plans for EL-22, a myostatin-engineered probiotic treatment designed to preserve muscle during weight loss with GLP-1 receptor agonists.

The FDA's feedback supports moving forward with an Investigational New Drug (IND) application for a Phase 2 clinical trial targeting overweight or obese patients. Bear Bull Traders, founded by Andrew Aziz, reaches 595,000 YouTube subscribers and maintains a network of over 7,000 active members and 100,000 newsletter subscribers globally.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), received positive FDA preliminary responses regarding their pre-IND meeting for EL-22, a novel engineered probiotic designed for obesity treatment in combination with GLP-1 receptor agonists.

The FDA's feedback supported that:

• Pharmacology studies demonstrate EL-22 activity
• Nonclinical studies adequately support safety and activity in overweight/obese populations
• Phase 1 study data and nonclinical studies appear sufficient for initiating Phase 2 trials

EL-22 targets the myostatin pathway to support muscle health during weight loss treatments. The company plans to file an IND application in 2025 to initiate Phase 2 clinical trials. Previous Phase 1 trials in South Korea showed the treatment was generally well-tolerated and safe in healthy volunteers.

PMGC Holdings Inc. (NASDAQ: PMGC) has announced signing a non-binding Letter of Intent (LOI) to acquire a U.S.-based custom IT packaging company. The acquisition target brings significant operational experience with nearly 15 years of history and serves over 300 commercial clients including data centers, technology manufacturers, and IT service providers.

The target company demonstrates strong market presence with 90% U.S.-based revenue and maintains recurring business relationships. The company is notably cash-flow positive, indicating established operational stability.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has entered into a Development and License Agreement with Yuva Biosciences to develop AI-powered therapies for obesity and cardiometabolic diseases. The collaboration will utilize YuvaBio's proprietary MitoNova™ platform to discover novel pharmaceutical treatments.

The partnership focuses on developing compounds that promote mitochondrial health and target cellular aging. YuvaBio will provide Northstrive with exclusive worldwide licensing rights for therapeutic products in cardiac diseases and obesity. The multi-phase collaboration includes in silico modeling, virtual compound screening, and experimental testing.

The agreement includes: (1) an upfront fee and phase-completion payments, (2) developmental milestone payments, and (3) royalties on net sales of therapeutic products containing compounds identified through the program.

PMGC Holdings Inc. (NASDAQ: ELAB) has announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission (SEC). The report is accessible on both the SEC's website and the company's investor relations platform.

The company states it is actively pursuing acquisition opportunities of operating businesses and assets as part of its strategic growth initiatives, aiming to drive revenue growth and enhance shareholder value.

PMGC Holdings (NASDAQ: ELAB) subsidiary NorthStrive Biosciences has announced a significant amendment to its existing licensing agreement with MOA Life Plus Co., The amendment expands NorthStrive's license rights for EL-32 and EL-22 to include all applications in animal health and feed additives.

The strategic move positions NorthStrive to tap into the U.S. animal health market, valued at $12.65 billion in 2024 with an expected CAGR of 7.97% from 2025 to 2030. The market growth is driven by innovations in companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations, and rising meat/milk consumption rates.